Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects

• Main Authors: Trottier AM, Cerquozzi S, Owen CJ
• Format: Article
• Language: English
• Published: Dove Medical Press 2017-12-01
• Series: Blood and Lymphatic Cancer : Targets and Therapy
• Subjects: BPDCN; Myeloid; Neoplasm; Cutaneous; Dendritic cell
• Online Access: https://www.dovepress.com/blastic-plasmacytoid-dendritic-cell-neoplasm-challenges-and-future-pro-peer-reviewed-article-BLCTT

Amy M Trottier, Sonia Cerquozzi, Carolyn J Owen Division of Hematology and Hematological Malignancies, University of Calgary, Foothills Medical Centre, Calgary, AB, Canada Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+ CD56+ myeloid malignancy that is challenging to diagnose and treat. BPDCN typically presents with nonspecific cutaneous lesions with or without extra-cutaneous manifestations before progressing to leukemia. Currently, there is no standard of care for the treatment of BPDCN and various approaches have been used including acute myeloid leukemia, acute lymphoblastic leukemia, and lymphoma-based regimens with or without stem cell transplantation. Despite these treatment approaches, the prognosis of BPDCN remains poor and there is a lack of prospective data upon which to base treatment decisions. Recent work examining the mutational landscape and gene expression profiles of BPDCN has identified a number of potential therapeutic targets. One such target is CD123, the α subunit of the human interleukin-3 receptor, which is the subject of intervention studies using the novel agent SL-401. Other investigational therapies include UCART123, T-cell immunotherapy, and venetoclax. Prospective trials are needed to determine the best treatment for this uncommon and aggressive neoplasm. Keywords: BPDCN, myeloid, neoplasm, cutaneous, dendritic cell